Trials / Conditions / Childhood Craniopharyngioma

Childhood Craniopharyngioma

13 registered clinical trials studyying Childhood Craniopharyngioma.

Status	Trial	Sponsor	Phase
Terminated	Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Sur NCT01964300	Pediatric Brain Tumor Consortium	Phase 2
Withdrawn	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452	Sue O'Dorisio	N/A
Terminated	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500	National Cancer Institute (NCI)	Phase 1
Completed	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335	National Cancer Institute (NCI)	Phase 1
Completed	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880	National Cancer Institute (NCI)	Phase 1
Completed	Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors NCT00919750	Children's Oncology Group	—
Completed	Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973	National Cancer Institute (NCI)	Phase 1
Completed	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780	National Cancer Institute (NCI)	Phase 1
Completed	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963	National Cancer Institute (NCI)	Phase 1
Completed	Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078	Children's Oncology Group	Phase 2